TARO PHARMACEUTICAL INDS LTD's ticker is TARO and the CUSIP is M8737E108. A total of 85 filers reported holding TARO PHARMACEUTICAL INDS LTD in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $24,162 | -0.9% | 640,735 | -0.4% | 8.90% | +15.1% |
Q2 2023 | $24,392 | +56.2% | 643,080 | +0.2% | 7.73% | +63.0% |
Q1 2023 | $15,611 | -16.6% | 641,910 | -0.4% | 4.74% | -18.0% |
Q4 2022 | $18,721 | -99.9% | 644,664 | +11.0% | 5.78% | +4.3% |
Q3 2022 | $17,412,000 | -17.1% | 580,793 | +0.0% | 5.54% | -20.1% |
Q2 2022 | $20,992,000 | -14.3% | 580,524 | +2.6% | 6.94% | -17.8% |
Q1 2022 | $24,483,000 | -9.3% | 565,951 | +5.0% | 8.44% | -9.9% |
Q4 2021 | $27,008,000 | -22.2% | 538,967 | -1.2% | 9.37% | -14.0% |
Q3 2021 | $34,715,000 | -11.3% | 545,583 | +0.3% | 10.89% | -18.0% |
Q2 2021 | $39,125,000 | -3.1% | 543,705 | -0.7% | 13.28% | -5.0% |
Q1 2021 | $40,388,000 | -0.6% | 547,639 | -1.1% | 13.98% | +17.8% |
Q4 2020 | $40,649,000 | +37.9% | 553,646 | +3.0% | 11.87% | +26.5% |
Q3 2020 | $29,475,000 | -15.0% | 537,378 | +3.0% | 9.38% | -0.5% |
Q2 2020 | $34,675,000 | +16.3% | 521,507 | +7.0% | 9.43% | -1.7% |
Q1 2020 | $29,821,000 | -0.2% | 487,275 | +43.4% | 9.59% | -5.9% |
Q4 2019 | $29,880,000 | – | 339,819 | – | 10.20% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Claret Asset Management Corp | 86,474 | $6,524,000 | 1.34% |
Analyst IMS Investment Management Services Ltd. | 28,438 | $2,143,000 | 0.64% |
ALGERT GLOBAL LLC | 20,876 | $1,575,000 | 0.59% |
Quantinno Capital Management LP | 9,351 | $706,000 | 0.48% |
Crestline Management, LP | 37,000 | $2,792,000 | 0.45% |
Empirical Finance, LLC | 9,561 | $721,000 | 0.20% |
BRANDES INVESTMENT PARTNERS, LP | 55,065 | $5,469,000 | 0.14% |
FORT, L.P. | 9,672 | $730,000 | 0.14% |
CAXTON ASSOCIATES LP | 8,865 | $669,000 | 0.13% |
ACADIAN ASSET MANAGEMENT LLC | 330,448 | $24,928,000 | 0.11% |